DBD Search
Grant R. Zimmermann
Managing Director of Business Development, Blavatnik Biomedical Accelerator
Displaying: 1 - 10 of 68 Results
Invention
RGMb-deficient T cells for overcoming resistance to immune checkpoint blockade
Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab at Harvard Medical School has identified that…
Investigators
- Arlene H. Sharpe
- Dennis Kasper
Invention
PD-L2 modulated dendritic cells for cancer immunotherapy
Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab has identified that dendritic cells (DCs) with…
Investigators
- Arlene H. Sharpe
- Dennis Kasper
Invention
Control of host homeostatic immunity by a microbiome-derived immunomodulatory lipid
Akkermansia muciniphila, a species of the human gut microbiome, has been robustly associated with positive systemic effects on host metabolism and obesity, favorable response to checkpoint blockade in cancer immunotherapy, and maintenance of…
Investigators
- Jon Clardy
Invention
Rapid point-of-care COVID-19 detection assay by RT-LAMP
The current SARS-CoV-2 pandemic has created an urgent need for rapid point-of-care diagnostic tools. Many of these tests are being developed and are achieving FDA approval. In the face of a sweeping pandemic, assays should require no specialized…
Investigators
- Constance L. Cepko
Invention
Extracellular vesicles for COVID-19 vaccine development
The laboratory of Quan Lu at the Harvard T.H. Chan School of Public Health has developed an innovative vaccine platform that features a novel antigen display technology that has been shown to elicit broadly neutralizing antibody responses from…
Investigators
- Quan Lu
Invention
Self-adjuvanting mRNA platform technology
Researchers in the lab of Prof. George Church at Harvard Medical School have developed a vaccine platform technology that can be applied to fields such as infectious diseases and oncology therapeutics. The team is looking to further demonstrate…
Investigators
- George M. Church
Invention
Compounds that block human cytomegalovirus by targeting the nuclear egress complex
Researchers in Dr. Donald Coen’s lab have identified molecules that inhibit human cytomegalovirus (HCMV) virion egress from the cell, effectively inhibiting HCMV replication. The team is looking to expand on these findings in collaborations that…
Investigators
- Donald M. Coen
Invention
Cancer Treatment through TRPA1 antagonism
Researchers in Joan Brugge’s lab have identified a new cancer therapeutic target in the ion channel transient receptor potential ankyrin 1 (TRPA1). The lab is seeking collaborations with industry partners to expand on these exciting findings. The…
Investigators
- Joan Brugge
Invention
Membrane protein nanoparticles for antigen presentation
Researchers in the lab of Dr. James Chou have engineered a new way to display membrane proteins to enhance vaccine immunogenicity using functionalized nanoparticles. The lab has successfully displayed several viral peptides using this technique and…
Investigators
- James J. Chou
Invention
Platform for AAV Delivery to Skin
Emerging startup: A platform technology from George Church's lab enables delivery of gene therapy via the skin. (Image credit: Carl Schoellhammer, Denitsa Milanova, Humberto Trevino, Cody Cleveland, Jeff Wyckoff, Anna Mandinova, George Church,…
Investigators
- George M. Church